GOTHENBURG, Sweden, April 25, 2024 /PRNewswire/ -- At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the record day. Re-election of Board members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee's proposal. Jón Sigurdsson was elected Chairman of the Board. Remuneration to the Board members is proposed to be in total SEK 3,300,000 of which SEK 1,200,000 to the Chairman of the Board, SEK 400,000 to each of the other members of the Board, SEK 150,000 to the Chairman of the Audit Committee and SEK 75,000 to each of the other members of the Audit Committee, SEK 100,000 to the Chairman of the Remuneration Committee and SEK 50,000 to each of the other members of the Remuneration Committee. The Election Committee proposes re-election of the auditor Deloitte AB for a period of three years after annual decisions and with unchanged remuneration principles. Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve to issue a maximum of 13,544,719 shares in total, corresponding to just below 10 percent of the company's share capital. Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on acquisition of the company's own shares. The Company can at no time hold more than 10 percent of the total shares in the Company. Resolution to implement a share-based incentive program including issue of a maximum number of 480,000 warrants to a wholly owned subsidiary of Vitrolife AB and approval that the subsidiary may transfer shares and/or warrants and of hedging activities. Gothenburg, April 25, 2024 VITROLIFE AB (publ) The Board The information was submitted for publication, through the agency of the contact persons set out above, at 25-04-2024 17:20 CET. Contact: Patrik Tolf, CFO, phone +46 (0) 31 766 90 21 This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails. This information was brought to you by Cision http://news.cision.com https://news.cision.com/vitrolife-ab--publ-/r/report-from-annual-general-meeting-of-vitrolife-ab--publ-,c3967068 The following files are available for download: https://mb.cision.com/Main/1031/3967068/2761483.pdf Report from Annual General Meeting of Vitrolife AB (publ) Cision View original content:https://www.prnewswire.com/news-releases/report-from-annual-general-meeting-of-vitrolife-ab-publ-302127752.html SOURCE Vitrolife AB (publ)
Report from Annual General Meeting of Vitrolife AB (publ)
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...